Issue link: http://osercommunicationsgroup.uberflip.com/i/499803
C h a i n D r u g s t o r e D a i l y S a t u r d a y, A p r i l 2 5 , 2 0 1 5 4 PRODUCT CAPABILITIES DRIVE AMNEAL'S NEXT PHASE OF GROWTH Amneal Pharmaceuticals LLC is taking the next step on its path of phenomenal growth by aligning resources to maintain the superior quality of its generic drugs even as it expands into new dosage forms and markets. All 11 of the company's state-of-the-art manufacturing plants worldwide are certified to exacting US FDA cGMP standards. Five expansive US and international research and devel- opment centers house Ph. D and M. D. level scientists with multi-disciplinary backgrounds in intellectual property, reg- ulatory, clinical, medical affairs, process technology, engineering and other disci- plines. In addition to a large, diversified portfolio of 82 approved generics, Amneal also counts 214 pipeline prod- ucts currently in development and 122 pending FDA approval. The company has established commercial capabilities with dedicated teams and operating units to develop, manufacture and market eight different dosage forms efficiently. Oral Solids are Amneal's best- known medications in tablets, caplets, softgels and new oral thin films that include 83 prod- ucts filed or in development with a US market value of $34 billion dol- lars, according to IMS Health. Abuse deterrent systems are being developed to make dosage forms difficult to manipulate or abuse through crushing, drug extraction or exposure from inten- tional or accidental overdose. Amneal understands the best meth- ods of handling dosage forms like Oral liquids, that comprise of solutions and suspensions, and the $3.2 billion market DAVID BIERNBAUM & ASSOCIATES HAS POWERED OVER 200 SUCCESSFUL OTC/HBC BRANDS David Biernbaum is President and Senior Consultant at David Biernbaum & Associates LLC and is one of the con- sumer goods and retail industry's fore- most business development consultants. A national sales specialist in the field of health and beauty, OTC and personal care, Biernbaum and his teams have had a major impact on more than 200 brands since 1977. As a consultant as well as a nationwide "master broker," he continues to have the magical touch. The latest and greatest examples: Australian Dream Arthritis Cream, Australian Dream Back Pain Cream and TriCalm Hydrogel. Biernbaum passionately explained: "Australian Dream is a 4-ounce jar of pain relief that retails for an average of $30 in drug stores like Walgreens, CVS and many of the regional drug chains and supermarkets. At one of the drug chains, we're selling nearly 4,000 pieces per week at $30 per unit even when not on promotion!" Australian Dream is also sold as a 2-ounce at Walmart, Target and a number of supermarkets, too. The brand has responded extremely well over these past two years to TV and radio advertis- ing. Biernbaum added, "We advertise every day of the year and we never stop." Biernbaum cautions that he doesn't take on all new clients, saying, "After 35 years in this business, I am very par- ticular and have strict criteria for the clients and brands I take on. I take on only products that offer the retailer points of differentiation, innovation, Continued on Page 29 Continued on Page 29 AN INDEPENDENT PUBLICATION NOT AFFILIATED WITH NACDS Lee M. Oser CEO and Editor-in-Chief Jules Denton Kim Forrester Paul Harris Associate Publishers Lorrie Baumann Editorial Director Richard Thompson JoEllen Lowry Jeanie Catron Associate Editors Yasmine Brown Andre Gressieux Graphic Designers Sarah Glenn Caitlyn Roach Customer Service Managers Heather Canale Jamie Green Don Kitch Tara Neal Show Logistics & Distribution Lynn Hilton Account Manager Enrico Cecchi European Sales Chain Drugstore Daily is published by Oser Communications Group ©2015 All rights reserved. Executive and editorial offices at: 1877 N. Kolb Road, Tucson, AZ 85715 520.721.1300/Fax: 520.721.6300 www.osercommunicationsgroup.com European offices located at Lungarno Benvenuto Cellini, 11, 50125 Florence, Italy